Cyclerion Therapeutics, Inc. (CYCN)

US — Healthcare Sector
Peers: KRON  LRMR  ADXN  ACHL  LIPO  SNTI  FENC  MNPR  AMTI  CDIO  SGTX  SONN  ZVSA  XFOR  AXLA  MGTA  KZR  CFRX  ZIVO  THRX  ERAS  FBRX 

Automate Your Wheel Strategy on CYCN

With Tiblio's Option Bot, you can configure your own wheel strategy including CYCN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CYCN
  • Rev/Share 0.8142
  • Book/Share 3.4351
  • PB 0.8384
  • Debt/Equity 0.0
  • CurrentRatio 4.2146
  • ROIC -0.3949

 

  • MktCap 9245059.0
  • FreeCF/Share -1.3419
  • PFCF -2.6954
  • PE -2.5004
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -0.3402

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 4
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Cyclerion Therapeutics, Inc. (CYCN)

  • IPO Date 2019-03-18
  • Website https://www.cyclerion.com
  • Industry Biotechnology
  • CEO Dr. Regina M. Graul Ph.D.
  • Employees 1
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.